Microbiome differences related to metformin intolerance among Black individuals with diabetes, a pilot cross-sectional study

[1]  I. Moreno-Indias,et al.  Gut microbiota of patients with type 2 diabetes and gastrointestinal intolerance to metformin differs in composition and functionality from tolerant patients. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Zitong Li,et al.  Metformin Exerts Anti-inflammatory and Mucus Barrier Protective Effects by Enriching Akkermansia muciniphila in Mice With Ulcerative Colitis , 2021, Frontiers in Pharmacology.

[3]  H. Ohno,et al.  Bifidobacterium bifidum G9-1 ameliorates soft feces induced by metformin without affecting its antihyperglycemic action , 2020, Bioscience of microbiota, food and health.

[4]  T. Nielsen,et al.  Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study , 2019, Diabetologia.

[5]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019 , 2018, Diabetes Care.

[6]  T. Sharpton,et al.  The influence of ethnicity and geography on human gut microbiome composition , 2018, Nature Medicine.

[7]  L. Zaharenko,et al.  Association of metformin administration with gut microbiome dysbiosis in healthy volunteers , 2018, PloS one.

[8]  D. Siscovick,et al.  Identifying prevalence and risk factors for metformin non-persistence: a retrospective cohort study using an electronic health record , 2018, BMJ Open.

[9]  W. D. de Vos,et al.  Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3 , 2018, PloS one.

[10]  Y. Hiromine,et al.  Effects of dosage and dosing frequency on the efficacy and safety of high‐dose metformin in Japanese patients with type 2 diabetes mellitus , 2017, Journal of diabetes investigation.

[11]  N. Mueller,et al.  Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid–Producing Microbiota in the Gut , 2016, Diabetes Care.

[12]  C. Bailey,et al.  Metformin and the gastrointestinal tract , 2016, Diabetologia.

[13]  Jens Roat Kultima,et al.  Disentangling the effects of type 2 diabetes and metformin on the human gut microbiota , 2016 .

[14]  Jeroen Raes,et al.  Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates , 2015, Gut.

[15]  C. Zhang,et al.  More effective glycaemic control by metformin in African Americans than in Whites in the prediabetic population. , 2015, Diabetes & metabolism.

[16]  F. Greenway,et al.  Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose Levels , 2015, Journal of diabetes science and technology.

[17]  C. Palmer,et al.  Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study , 2014, Diabetes.

[18]  GwangPyo Ko,et al.  Effect of Metformin on Metabolic Improvement and Gut Microbiota , 2014, Applied and Environmental Microbiology.

[19]  James R. Brown,et al.  Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus , 2014, PloS one.

[20]  L. Williams,et al.  Differing effects of metformin on glycemic control by race-ethnicity. , 2014, The Journal of clinical endocrinology and metabolism.

[21]  S. Saydah,et al.  The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010 , 2013, Diabetes Care.

[22]  Myung-Shik Lee,et al.  An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice , 2013, Gut.

[23]  Curtis Huttenhower,et al.  Chapter 12: Human Microbiome Analysis , 2012, PLoS Comput. Biol..

[24]  Ian B. Jeffery,et al.  The microbiota link to irritable bowel syndrome , 2012, Gut microbes.

[25]  H. Sokol,et al.  Increase in fecal primary bile acids and dysbiosis in patients with diarrhea‐predominant irritable bowel syndrome , 2012, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[26]  G. Bray,et al.  Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study , 2012, Diabetes Care.

[27]  Thomas E. Moritz,et al.  Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). , 2009, Diabetes research and clinical practice.

[28]  C. Bailey,et al.  Metformin and the intestine , 2008, Diabetologia.

[29]  J. Corander,et al.  The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. , 2007, Gastroenterology.

[30]  Johan P Mackenbach,et al.  Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients: a review. , 2005, Diabetes care.

[31]  Charles Maynard,et al.  Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. , 2003, Diabetes care.

[32]  R. Klein,et al.  Is the Risk of Diabetic Retinopathy Greater in Non-Hispanic Blacks and Mexican Americans Than in Non-Hispanic Whites With Type 2 Diabetes?: A U.S. population study , 1998, Diabetes Care.

[33]  H. Howlett,et al.  Effect of metformin on bile salt circulation and intestinal motility in Type 2 diabetes mellitus , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[34]  P. Savage,et al.  Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. , 1989, The New England journal of medicine.

[35]  P. Dandona,et al.  Diarrhea and Metformin in a Diabetic Clinic , 1983, Diabetes Care.

[36]  P. Valle,et al.  Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. , 2018, The lancet. Gastroenterology & hepatology.

[37]  H. Bönisch,et al.  Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.